Blood-based liquid biopsy for diagnosis and surveillance of primary upper tract urothelial carcinoma: road to emerging novel biomarker

You have accessJournal of UrologyCME1 Apr 2023PD46-02 BLOOD-BASED LIQUID BIOPSY FOR DIAGNOSIS AND SURVEILLANCE OF PRIMARY UPPER TRACT UROTHELIAL CARCINOMA: ROAD TO EMERGING NOVEL BIOMARKER Alireza Ghoreifi, Stephanie Shishido, George Courcoubetis, Salmaan Sayeed, Amy Huang, Andrew Hung, Anne Schuckman, Monish Aron, Mihir Desai, Siamak Daneshmand, Inderbir Gill, Peter Kuhn, Jeremy Mason, and Hooman Djaladat Alireza GhoreifiAlireza Ghoreifi More articles by this author , Stephanie ShishidoStephanie Shishido More articles by this author , George CourcoubetisGeorge Courcoubetis More articles by this author , Salmaan SayeedSalmaan Sayeed More articles by this author , Amy HuangAmy Huang More articles by this author , Andrew HungAndrew Hung More articles by this author , Anne SchuckmanAnne Schuckman More articles by this author , Monish AronMonish Aron More articles by this author , Mihir DesaiMihir Desai More articles by this author , Siamak DaneshmandSiamak Daneshmand More articles by this author , Inderbir GillInderbir Gill More articles by this author , Peter KuhnPeter Kuhn More articles by this author , Jeremy MasonJeremy Mason More articles by this author , and Hooman DjaladatHooman Djaladat More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003359.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Blood-based liquid biopsy has emerged as a novel diagnostic and prognostic biomarker in cancer patients, yet the efficacy of this test in patients with upper tract urothelial carcinoma (UTUC) is unknown. The aim of this study is to explore the feasibility of a liquid biopsy in the diagnosis and surveillance of primary UTUC. METHODS: In this prospective pilot study, under an IRB-approved protocol (#HS-19-00886), blood samples were collected between May 2021 and September 2022 from primary UTUC patients before surgical intervention with curative intent as well as follow-up visits. The samples were analyzed using the third generation comprehensive high-definition single cell assay (HDSCA3.0) to detect rare cells (e.g., circulating tumor cells [CTCs]) and other rare events (e.g., large extracellular vesicles [LEVs]) (Figure 1-A). The findings of pre-surgery liquid biopsies were compared to the blood samples of normal donors (NDs) who had no known pathology. Follow-up samples were compared to the baseline findings. RESULTS: A total of 22 UTUC patients and 50 NDs were included in the analysis. Pathologic staging of UTUC patients revealed 13 non-muscle invasive (更多